Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

TAMER BEHMAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1730257619
CMS profile
351372
Location
CARTERET, NJ

General Payments · PY2018–2024

$73,589.68

  • Reported across 37 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$32,216.98

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $32,200.00 12
Food and Beverage $16.98 1

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $32,200.00 12
Celgene Corporation $16.98 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $14.14 1
PY2019 $11.40 1
PY2022 $20,475.00 10
PY2023 $20,872.16 12
PY2024 $32,216.98 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 2018201920222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Celgene Corporation $16.98 07/22/2024 Food and Beverage Undisputed 01/23/2026 1101103934 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,600.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137484547 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,600.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137484551 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137484555 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137484559 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137484563 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137484567 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137484571 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137484574 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137484578 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137484582 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137484586 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,700.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137484590 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.